John Ironside, MD
Neurology · Little Rock, ARNPI 1891727855
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,404 of the $9,673 with a category attached, or 76.5%. 28 manufacturers reported payments, led by AbbVie at 32.7% of the total.
Across 430 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Novartis$1K
- Amgen$654
- Pfizer$366
- Lilly USA, LLC$340
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$2,10022%
- Travel & lodging$460%
- Food & beverage$7,40477%
- Education$1241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 197 | $3,166 |
| Teva Pharmaceuticals USA, Inc. | 6 | $2,287 |
| Novartis | 60 | $1,073 |
| Amgen | 44 | $654 |
| Pfizer | 23 | $366 |
| Lilly USA, LLC | 14 | $340 |
| Lundbeck LLC | 6 | $280 |
| EMD Serono, Inc. | 12 | $169 |
| Sanofi | 8 | $166 |
| Biohaven Pharmaceuticals, Inc. | 9 | $161 |
| Amneal Pharmaceuticals LLC | 7 | $135 |
| Springworks Therapeutics, Inc. | 4 | $125 |
| Argenx US, Inc. | 5 | $92 |
| Genentech USA, Inc. | 4 | $81 |
| AstraZeneca | 4 | $78 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $78 |
| Bristol Myers Squibb | 4 | $59 |
| UCB, Inc. | 2 | $55 |
| Supernus Pharmaceuticals, Inc. | 3 | $53 |
| CSL Behring | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Biogen | 2 | $37 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Neurelis, Inc. | 1 | $29 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,673 in reported general payments places this provider in the 75th percentile of 93 neurology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 39 | $326,819 |
| AustedoDeutetrabenazine | 21 | $200,499 |
| Nurtec OdtRimegepant Sulfate | 56 | $109,021 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $93,204 |
| CopaxoneGlatiramer Acetate | 11 | $64,115 |
| UbrelvyUbrogepant | 45 | $63,117 |
| Aimovig AutoinjectorErenumab-Aooe | 41 | $58,589 |
| QuliptaAtogepant | 27 | $43,322 |
| AptiomEslicarbazepine Acetate | 13 | $34,798 |
| Emgality PenGalcanezumab-Gnlm | 15 | $15,143 |
| Gabapentin | 386 | $6,991 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 344 | $6,453 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 56 | $6,104 |
| Pregabalin | 97 | $4,581 |
| Eletriptan HbrEletriptan Hydrobromide | 14 | $4,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $39 | $326,81939 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $2,287 | $264,61432 claims |
| PfizerNurtec Odt | $366 | $109,02156 claims |
| AbbVieUbrelvy, Qulipta | $3,166 | $106,43972 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $135 | $5,66976 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 93 neurology providers in Arkansas.
Other neurology in Little Rock
- Shitiz SriwastavaLittle Rock$59K
- Elizabeth SullivanLittle Rock$33K
- Kapil AryaLittle Rock$16K
- Robert SilzerLittle Rock$14K
- Bradley BoopLittle Rock$13K
- Duane BirkyLittle Rock$12K
- Abdel Rahman SalehLittle Rock$10K
- Christopher WrightLittle Rock$9K
- Srilatha ThadurLittle Rock$7K
- Mitchell KaufmanLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.